Filing Details
Monopar Therapeutics (NASDAQ:MNPR) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:MNPR
Monopar Therapeutics (MNPR) Files Quarterly Report for Q0
Monopar Therapeutics (NASDAQ:MNPR) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
At publication ·
What changed
Monopar Therapeutics (NASDAQ:MNPR) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Monopar Therapeutics filed its Q0 2026 quarterly report (Form 10-Q) on August 12, 2026 with the SEC.
- The company's stock trades at $114.90 with a market capitalization of $514.6 million.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance, though specific revenue figures were not disclosed in this summary.
Market Context
Monopar Therapeutics's stock currently trades at $114.90 with a market capitalization of $514.6M.
The 10-Q provides Monopar Therapeutics's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Monopar Therapeutics are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MNPR Stock Page
Frequently Asked Questions
Where can I read MNPR's SEC filings?
Browse all filings on our MNPR SEC filings page.
What types of SEC filings does Monopar Therapeutics file?
Public companies like Monopar Therapeutics file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.